Estudo de pré-formulação para a obtenção de uma formulação de captopril para uso pediátrico

Abstract

Nowadays, drugs used in children are adapted from solid dosage forms developed for adults. Captopril in solid dosage form is widely adapted in hospitals into a liquid formulation. Its stability in aqueous solutions is reduced because it undergoes oxidation, forming captopril disulfide. In order to ensure a stable and accurate dosage form, a pre-formulation study was developed for obtaining a stable formulation of a powder for preparation of a captopril solution for pediatric use. The compatibility between drug and possible excipients were evaluated by differential scanning calorimetry (DSC) and the captopril thermic behavior, through thermogravimetric analysis (TG) and differential thermal analysis (DTA). Then, particle size and indirect flow measures of captopril and excipients were analyzed. For solution studies, different formulations were obtained through factorial design, varying the EDTA concentration (0.005 and 0.1%) and pH (2.5, 4.0 e 5.5) in distilled and mineral water, which were stored at 60°C and analyzed over twelve days by HPLC to evaluate the stability of captopril. In the DSC curves of captopril mixtures with preservatives, sucralose and citric acid, the isolated thermal events were not maintained. In the other binary mixtures, the events corresponding to each component were preserved in the curves, indicating compatibility between substances. There was a major difference in the distribution and average particles diameters and density of buffering agents in comparison to other substances, which can cause segregation of the powder mixture. From the study of the solutions stability it was found that the variables interfere significantly (p = 0.05) in the captopril content, the pH being the most important factor. The interactions between variables were significant, with greater stability around pH 4.0, higher EDTA concentrations and use of mineral water. Based on the results, it can be concluded that development of a stable captopril formulation is viable if strategic measures are adopted in order to avoid segregation of the powders constituents of the formulation.